T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) – Pipeline Review, H2 2016’, provides in depth analysis on T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted pipeline therapeutics.

The report provides comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)

The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects

The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biotest AG

CEL-SCI Corporation

Fountain Biopharma Inc.

Immupharma Plc

Inovio Pharmaceuticals, Inc.

TaiMed Biologics Inc.

United Biomedical, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Overview 8

Therapeutics Development 9

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Stage of Development 9

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Therapy Area 10

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Indication 11

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Companies 14

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Universities/Institutes 16

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development 25

Biotest AG 25

CEL-SCI Corporation 26

Fountain Biopharma Inc. 27

Immupharma Plc 28

Inovio Pharmaceuticals, Inc. 29

TaiMed Biologics Inc. 30

United Biomedical, Inc. 31

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles 32

3BNC-117 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CEL-1000 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

forigerimod acetate - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

HIV vaccine 2 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ibalizumab - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ibalizumab biosimilar - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ibalizumab second generation - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

M-48U1 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

MAX-16H5 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Monoclonal Antibody to Inhibit CD4 for HIV - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Activate CD4 for HIV - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecules to Target CD4 for HIV - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

TMB-360 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

tregalizumab - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

UB-421 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VRC-01 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Projects 60

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products 64

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Featured News & Press Releases 65

Jun 07, 2016: First European Patients Commence Dosing In Lupuzor's Pivotal Phase III Study 65

May 24, 2016: Theratechnologies Announces that

82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial 65

May 06, 2016: Antibody therapy opens door to potential new treatment for HIV 66

May 05, 2016: Broadly neutralizing antibodies improve immune response; clear HIV reservoirs 67

Apr 27, 2016: Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial 68

Apr 27, 2016: Single Antibody Infusions Provide Durable Protection Against HIV-Like Virus in Monkeys 68

Mar 09, 2016: First European site opened in France and patient recruitment commences in Lupuzor pivotal phase III study 69

Feb 15, 2016: First US Patients Commence Dosing In Lupuzor Pivotal Phase III Study 70

Dec 15, 2015: Over 70 Lupus Specialists Gather in Paris for Lupuzor’s Phase III Investigators Meeting 70

Dec 07, 2015: Lupuzor Pivotal Phase III Trial Recruiting First US Lupus Patients 71

Nov 09, 2015: Biotest to present data from TREAT 2b trial at The American College of Rheumatology 2015 Annual Meeting 71

Nov 04, 2015: ImmuPharma Provides Lupuzor Phase III Pivotal Trial Update 72

Jul 27, 2015: Clinicaltrials.Gov Registration Of Lupuzor Pivotal Phase III Trial 73

Jun 25, 2015: Lupuzor's Founder, Dr Slyviane Muller - Awarded Medal of Innovation from CNRS for Lupuzor 73

Apr 24, 2015: Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million 74

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Biotest AG, H2 2016 25

Pipeline by CEL-SCI Corporation, H2 2016 26

Pipeline by Fountain Biopharma Inc., H2 2016 27

Pipeline by Immupharma Plc, H2 2016 28

Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 29

Pipeline by TaiMed Biologics Inc., H2 2016 30

Pipeline by United Biomedical, Inc., H2 2016 31

Dormant Projects, H2 2016 60

Dormant Projects (Contd..1), H2 2016 61

Dormant Projects (Contd..2), H2 2016 62

Dormant Projects (Contd..3), H2 2016 63

Discontinued Products, H2 2016 64

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports